An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented to Richard Pazdur, MD, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois. Pazdur will accept the award and give remarks during the meeting’s Opening Ceremony on Sunday, April 27, which begins at 7:45 a.m. CT.

In places like Australia, where metropolitan areas are separated by an entire continent, donor hearts used to go unused simply because transplant teams couldn’t get the organ to a recipient in time. Emily Granger, MBBS, cardiothoracic and heart and lung transplant surgeon at St. Vincent's Hospital, Sydney, Australia, addressed organ transportation time at today’s Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation (ISHLT) in Boston.